Glenmark Pharmaceuticals Limited, through its US subsidiary Glenmark Pharmaceuticals Inc. USA, launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug Vimpat Injection, of UCB, Inc.
According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market recorded annual sales of approximately $15.2 million, including brand and all available therapeutic equivalents. Glenmark's product is approved only for the indications listed in its approved label and is not marketed for all reference listed drug indications.
Marc Kikuchi, President and Business Head, North America, said the launch represents the disciplined execution of a strategy to build a broader, differentiated product portfolio in the United States. Expanding the injectable portfolio enhances Glenmark's ability to meet healthcare provider needs while improving patient access to quality, affordable treatment options, he said.
Glenmark Pharmaceuticals Ltd (BSE: 532296, NSE: GLENMARK) operates as a global research-led pharmaceutical company with 11 manufacturing facilities across four continents, six R&D centres, and a commercial presence in 80 countries. Glenmark's portfolio spans branded, innovative, generics, and consumer health products across respiratory, dermatology, and oncology therapeutic areas.
Glenmark was ranked among the top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. Glenmark's US subsidiary is based in Elmwood Park, New Jersey.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.